# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Financial Results for the Fiscal Year Ended December 31, 2022 Revenues increased by 49% to $3,805,017 for the year ended Decem...
https://neovasc.com/newsreleases/neovasc-shareholders-approve-acquisition-by-shockwave-medical/
HC Wainwright & Co. analyst Vernon Bernardino downgrades Neovasc (NASDAQ:NVCN) from Buy to Neutral.
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Tuesday.
Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, dec...
Neovasc Inc. (NASDAQ: NVCN) shares are trading higher after ShockWave Medical, Inc. (NASDAQ: SWAV) announced it would acquire t...
U.S. stocks traded mostly lower midway through trading, with the Dow Jones dropping over 300 points on Tuesday.